Malcolm W. MacNab
Technik-/Wissenschafts-/F&E-Leiter bei HaptoGuard, Inc.
Profil
Malcolm W.
MacNab has served as Vice President of Clinical Development for Alteon, Inc. since July 2006.
Prior to joining Alteon, he served as Vice President of Clinical Development for HaptoGuard from 2004 to 2006.
From 1997 to 2004, Dr. MacNab served as Vice President of Cardiovascular and Metabolism Clinical Development and Medical Affairs at Novartis.
Prior to joining Novartis, he was Vice President in Cardiovascular Development at CIBA Pharmaceuticals.
Dr. MacNab received an MD and a PhD in Vascular Pharmacology from Temple University in Philadelphia and post-graduate training in Internal Medicine and Hematology at the Medical College of Pennsylvania.
Aktive Positionen von Malcolm W. MacNab
Unternehmen | Position | Beginn |
---|---|---|
HaptoGuard, Inc.
HaptoGuard, Inc. BiotechnologyHealth Technology HaptoGuard, Inc. develops and commercializes therapeutics for inflammatory diseases. Its products include orally bioavailability and organ selenium mimics of glutathione peroxides that metabolize lipid peroxides. It develops products to research, diagnose, treat, and prevent diseases associated with damage from free radical and reactive oxygen species and diseases of oxidative stress. The company is headquartered in Fort Lee, NJ. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Malcolm W. MacNab
Unternehmen | Position | Ende |
---|---|---|
SYNVISTA THERAPEUTICS, INC. | Corporate Officer/Principal | 31.12.2007 |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2004 |
Ciba Pharmaceuticals | Corporate Officer/Principal | - |
Ausbildung von Malcolm W. MacNab
Temple University (Pennsylvania) | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SYNVISTA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
HaptoGuard, Inc.
HaptoGuard, Inc. BiotechnologyHealth Technology HaptoGuard, Inc. develops and commercializes therapeutics for inflammatory diseases. Its products include orally bioavailability and organ selenium mimics of glutathione peroxides that metabolize lipid peroxides. It develops products to research, diagnose, treat, and prevent diseases associated with damage from free radical and reactive oxygen species and diseases of oxidative stress. The company is headquartered in Fort Lee, NJ. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Ciba Pharmaceuticals |